Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna. In ...

Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...

U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird ...

Arbutus Biopharma and Genevant Sciences are broadening the scope of their patent infringement claims against Moderna with ...

Moderna, Inc. ( NASDAQ: MRNA) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET All right, well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the Medicines and Healthcare products ...

For now, Moderna may be a good stock to put on a watch list, but it's likely too risky and volatile for the vast majority of ...

The Trump administration confirmed it is reevaluating a $590 million human bird flu vaccine contract awarded to Moderna in ...

Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: ...